SABBY MANAGEMENT LLC
Q3 2022 Form 13-F
SPICEWOOD, TEXAS
CIK 0001535610
· CRD 162659
· Exempt reporting adviser
Consolidated report · includes
1 manager
since Q3 2024
$79.3M Reported Value Total
SABBY MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $506,127,398, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Discretionary Manager
Private funds (Form ADV)
2 funds
· $197.4M gross asset value
Private Equity Fund: $181.5M · Hedge Fund: $15.8M
Source: Form ADV filed 2026-07-08
Reported value
$79.3M
Quarter over quarter
-8.7%
Holdings
82
Top-10 concentration
54.5%
Filing Structure
Reports holdings for
- Hal Mintz (not a 13F filer in our records) · since Q3 2024 · declared by one filing
- Mintz Hal · File #028-13502 · Q2 2013 – Q1 2025 · declared by one filing
Key People
Form ADV owners & control persons
Hal David Mintz
PRINCIPAL AND MANAGING MEMBER OF SABBY MANAGEMENT, LLC AND SABBY CAPITAL, LLC
Robert Alan Grundstein
CHIEF COMPLIANCE OFFICER OF SABBY MANAGEMENT, LLC AND SABBY CAPITAL, LLC
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2022 13F record
Q3 2022 13F filing summary
| Period of report | September 30, 2022 |
|---|---|
| Filed | November 14, 2022 |
| Form | 13F-HR |
| Reported value | $79.3M |
| Positions | 82 |
| Change in reported value | -46.1% |
| New positions | 30 |
| Exited positions | 23 |
| Position turnover | 50.5% |
| Top-10 concentration | 54.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
16 | $110.5M |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $45.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
25 | $69.5M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
29 | $86.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
33 | $55.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
36 | $34.0M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
16 | $76.9M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
27 | $186.4M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
27 | $148.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
43 | $173.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
46 | $100.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
66 | $136.6M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
68 | $122.2M |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $114.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
89 | $114.0M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
82 | $79.3M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
75 | $147.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
83 | $669.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
103 | $687.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
93 | $739.9M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BIL P SPDR SER TR | $10.1M | 12.76% |
| 2 | NYC P ISHARES TR | $6.4M | 8.09% |
| 3 | BGXXQ BRIGHT GREEN CORP | $5.1M | 6.49% |
| 4 | NVCT NUVECTIS PHARMA INC | $4.5M | 5.66% |
| 5 | BCTX P BRIACELL THERAPEUTICS CORP | $3.2M | 4.01% |
| 6 | TCDAQ C TRICIDA INC | $3.0M | 3.79% |
| 7 | DOGZ DOGNESS INTL CORP | $2.8M | 3.59% |
| 8 | BLRX BIOLINERX LTD | $2.8M | 3.54% |
| 9 | AKTX AKARI THERAPEUTICS PLC | $2.6M | 3.26% |
| 10 | ZVRA P KEMPHARM INC | $2.6M | 3.26% |
| 11 | ATNM P ACTINIUM PHARMACEUTICALS INC | $1.6M | 2.0% |
| 12 | ZVRA KEMPHARM INC | $1.6M | 1.96% |
| 13 | COCPD COCRYSTAL PHARMA INC | $1.5M | 1.94% |
| 14 | PMCB PHARMACYTE BIOTECH INC | $1.4M | 1.72% |
| 15 | HCDIZ HARBOR CUSTOM DEVELOPMENT INC | $1.3M | 1.6% |
| 16 | VRPX VIRPAX PHARMACEUTICALS INC | $1.3M | 1.58% |
| 17 | NISN NISUN INTL ENT DVPMT GP CO LTD | $1.1M | 1.43% |
| 18 | RCON RECON TECHNOLOGY LTD | $1.1M | 1.42% |
| 19 | PULM PULMATRIX INC | $1.1M | 1.41% |
| 20 | ONCO BLUE WATER VACCINES INC | $944.0K | 1.19% |
Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.